These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 16551740)

  • 1. Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome.
    Gambineri A; Vicennati V; Genghini S; Tomassoni F; Pagotto U; Pasquali R; Walker BR
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2295-302. PubMed ID: 16551740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates.
    Tsilchorozidou T; Honour JW; Conway GS
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5907-13. PubMed ID: 14671189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of 11beta-hydroxysteroid dehydrogenase 1 and 2 in subcutaneous adipose tissue of lean and obese women with and without polycystic ovary syndrome.
    Svendsen PF; Madsbad S; Nilas L; Paulsen SK; Pedersen SB
    Int J Obes (Lond); 2009 Nov; 33(11):1249-56. PubMed ID: 19704410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A combination of polymorphisms in HSD11B1 associates with in vivo 11{beta}-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome.
    Gambineri A; Tomassoni F; Munarini A; Stimson RH; Mioni R; Pagotto U; Chapman KE; Andrew R; Mantovani V; Pasquali R; Walker BR
    Eur J Endocrinol; 2011 Aug; 165(2):283-92. PubMed ID: 21622477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of the hexose-6-phosphate dehydrogenase gene R453Q and 11beta-hydroxysteroid dehydrogenase type 1 gene 83557insA polymorphisms in the polycystic ovary syndrome.
    San Millán JL; Botella-Carretero JI; Alvarez-Blasco F; Luque-Ramírez M; Sancho J; Moghetti P; Escobar-Morreale HF
    J Clin Endocrinol Metab; 2005 Jul; 90(7):4157-62. PubMed ID: 15827106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
    Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
    J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-specific dysregulation of 11β-hydroxysteroid dehydrogenase type 1 in overweight/obese women with polycystic ovary syndrome compared with weight-matched controls.
    Gambineri A; Fanelli F; Tomassoni F; Munarini A; Pagotto U; Andrew R; Walker BR; Pasquali R
    Eur J Endocrinol; 2014 Jul; 171(1):47-57. PubMed ID: 24743397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of 11β-hydroxysteroid dehydrogenase type 1 in visceral and subcutaneous adipose tissues of patients with polycystic ovary syndrome is associated with adiposity.
    Mlinar B; Marc J; Jensterle M; Bokal EV; Jerin A; Pfeifer M
    J Steroid Biochem Mol Biol; 2011 Feb; 123(3-5):127-32. PubMed ID: 21147223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addressing the role of 11β-hydroxysteroid dehydrogenase type 1 in the development of polycystic ovary syndrome and the putative therapeutic effects of its selective inhibition in a preclinical model.
    Li X; Hu S; Zhu Q; Yao G; Yao J; Li J; Wang Y; Ding Y; Qi J; Xu R; Zhao H; Zhu Z; Du Y; Sun K; Sun Y
    Metabolism; 2021 Jun; 119():154749. PubMed ID: 33722534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variants implicated in cortisone reductase deficiency do not contribute to susceptibility to common forms of polycystic ovary syndrome.
    Draper N; Powell BL; Franks S; Conway GS; Stewart PM; McCarthy MI
    Clin Endocrinol (Oxf); 2006 Jul; 65(1):64-70. PubMed ID: 16817821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased clearance of cortisol by 5beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome.
    Gambineri A; Forlani G; Munarini A; Tomassoni F; Cognigni GE; Ciampaglia W; Pagotto U; Walker BR; Pasquali R
    J Endocrinol Invest; 2009 Mar; 32(3):210-8. PubMed ID: 19542736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity.
    Rask E; Walker BR; Söderberg S; Livingstone DE; Eliasson M; Johnson O; Andrew R; Olsson T
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3330-6. PubMed ID: 12107245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome.
    Vassiliadi DA; Barber TM; Hughes BA; McCarthy MI; Wass JA; Franks S; Nightingale P; Tomlinson JW; Arlt W; Stewart PM
    J Clin Endocrinol Metab; 2009 Sep; 94(9):3558-66. PubMed ID: 19567518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency.
    Draper N; Walker EA; Bujalska IJ; Tomlinson JW; Chalder SM; Arlt W; Lavery GG; Bedendo O; Ray DW; Laing I; Malunowicz E; White PC; Hewison M; Mason PJ; Connell JM; Shackleton CH; Stewart PM
    Nat Genet; 2003 Aug; 34(4):434-9. PubMed ID: 12858176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression of 11β-HSDs, GR, and H6PDH in subcutaneous adipose tissue from polycystic ovary syndrome subjects.
    Li S; Tao T; Wang L; Mao X; Zheng J; Zhao A; Liu W
    Horm Metab Res; 2013 Oct; 45(11):802-7. PubMed ID: 23979790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The R453Q and D151A polymorphisms of hexose-6-phosphate dehydrogenase gene (H6PD) influence the polycystic ovary syndrome (PCOS) and obesity.
    Martínez-García MA; San-Millán JL; Escobar-Morreale HF
    Gene; 2012 Apr; 497(1):38-44. PubMed ID: 22306327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
    Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 11Beta-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization.
    Paulsen SK; Pedersen SB; Fisker S; Richelsen B
    Obesity (Silver Spring); 2007 Aug; 15(8):1954-60. PubMed ID: 17712112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variation in exon 17 of INSR is associated with insulin resistance and hyperandrogenemia among lean Indian women with polycystic ovary syndrome.
    Mukherjee S; Shaikh N; Khavale S; Shinde G; Meherji P; Shah N; Maitra A
    Eur J Endocrinol; 2009 May; 160(5):855-62. PubMed ID: 19211708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen levels and metabolic parameters are associated with a genetic variant of F13A1 in women with polycystic ovary syndrome.
    Schweighofer N; Lerchbaum E; Trummer O; Schwetz V; Pilz S; Pieber TR; Obermayer-Pietsch B
    Gene; 2012 Aug; 504(1):133-9. PubMed ID: 22565190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.